Cargando…
Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?
OBJECTIVES: The aim of this study was to compare post-authorisation measures (PAMs) from the European Medicines Agency (EMA) with data requests in fixed-termed conditional appraisals of early benefit assessments from the German Federal Joint Committee (G-BA). METHODS: Medicinal products with complet...
Autores principales: | Ruof, Jörg, Staab, Thomas, Dintsios, Charalabos-Markos, Schröter, Jakob, Schwartz, Friedrich Wilhelm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042914/ https://www.ncbi.nlm.nih.gov/pubmed/27687714 http://dx.doi.org/10.1186/s13561-016-0124-4 |
Ejemplares similares
-
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019) -
“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
por: Staab, Thomas R., et al.
Publicado: (2018) -
Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
por: Ruof, Jörg, et al.
Publicado: (2013) -
The impact of HTA reports on health policy: a systematic review
por: Gerhardus, Ansgar, et al.
Publicado: (2005) -
SVHC in imported articles: REACH authorisation requirement justified under WTO rules
por: Schenten, Julian, et al.
Publicado: (2016)